INT199413

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 0.32
Pain Relevance 0.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

OR3A4P (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 11 72.76 Quite High
mu opioid receptor 5 72.08 Quite High
Bioavailability 1 42.00 Quite Low
Paracetamol 2 31.48 Quite Low
opiate 9 5.00 Very Low Very Low Very Low
Versed 7 5.00 Very Low Very Low Very Low
Opioid 5 5.00 Very Low Very Low Very Low
rapifen 4 5.00 Very Low Very Low Very Low
carbamazepine 3 5.00 Very Low Very Low Very Low
Morphine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Head Trauma 1 81.08 Quite High
Breast Cancer 1 64.76 Quite High
Cancer 6 60.48 Quite High
Toxicity 16 55.76 Quite High
Hemorrhage 1 38.12 Quite Low
Hematuria 1 37.56 Quite Low
Hepatotoxicity 1 32.08 Quite Low
Arrhythmia Under Development 3 7.68 Low Low
Disease 3 5.00 Very Low Very Low Very Low
Hypertension 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of tyrosine phosphatase activity (3,4-dephostatin) blocked the synergy between MNTX and temsirolimus and increased VEGF-induced tyrosine phosphorylation of Src with enhanced PI3 kinase and mTOR Complex 2-dependent phosphorylation of Akt and subsequent activation of mTOR Complex 1 (rapamycin and temsirolimus target), while silencing Src, Akt or mTOR complex 2 components blocked VEGF-induced angiogenic events.


Negative_regulation (Inhibition) of 3,4-dephostatin
1) Confidence 0.01 Published 2010 Journal J Angiogenes Res Section Abstract Doc Link PMC2831839 Disease Relevance 0.12 Pain Relevance 0.07
Silybin, the major constituent of milk thistle (Sylybum marianum), is a mechanism-based inhibitor of CPY3A4 (Sridar et al 2004).
Negative_regulation (inhibitor) of CPY3A4
2) Confidence 0.01 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox